BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2424286)

  • 1. Targets and markers of selective action of tiazofurin.
    Weber G; Natsumeda Y; Pillwein K
    Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Control of enzymic programs and nucleotide pattern in cancer cells by acivicin and tiazofurin.
    Weber G; Natsumeda Y; Lui MS; Faderan MA; Liepnieks JJ; Elliott WL
    Adv Enzyme Regul; 1984; 22():69-93. PubMed ID: 6206692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
    Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
    J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical mechanisms of resistance to tiazofurin.
    Jayaram HN
    Adv Enzyme Regul; 1985; 24():67-89. PubMed ID: 3835825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of resistance to tiazofurin in hepatoma 3924A.
    Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
    Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme-pattern-targeted chemotherapy with tiazofurin and allopurinol in human leukemia.
    Weber G; Jayaram HN; Lapis E; Natsumeda Y; Yamada Y; Yamaji Y; Tricot GJ; Hoffman R
    Adv Enzyme Regul; 1988; 27():405-33. PubMed ID: 2907968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase.
    Yamada Y; Natsumeda Y; Weber G
    Biochemistry; 1988 Mar; 27(6):2193-6. PubMed ID: 2897864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of purine and pyrimidine metabolism by insulin and by resistance to tiazofurin.
    Weber G; Lui MS; Jayaram HN; Pillwein K; Natsumeda Y; Faderan MA; Reardon MA
    Adv Enzyme Regul; 1985; 23():81-99. PubMed ID: 3907307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiazofurin: molecular and clinical action.
    Weber G; Prajda N; Abonyi M; Look KY; Tricot G
    Anticancer Res; 1996; 16(6A):3313-22. PubMed ID: 9042306
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin.
    Yamada Y; Natsumeda Y; Yamaji Y; Jayaram HN; Tricot GJ; Hoffman R; Weber G
    Leuk Res; 1989; 13(2):179-84. PubMed ID: 2564451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
    Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
    Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential impact of tiazofurin and ribavirin on the enzymic program of the bone marrow.
    Prajda N; Hata Y; Abonyi M; Singhal RL; Weber G
    Cancer Res; 1993 Dec; 53(24):5982-6. PubMed ID: 7903199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tiazofurin-induced selective depression of NAD content in hepatoma 3924A.
    Liepnieks JJ; Faderan MA; Lui MS; Weber G
    Biochem Biophys Res Commun; 1984 Jul; 122(1):345-9. PubMed ID: 6743337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular impact of inhibition of IMP dehydrogenase activity by tiazofurin.
    Weber G; Yamaji Y; Olah E; Natsumeda Y; Jayaram HN; Lapis E; Zhen WN; Prajda N; Hoffman R; Tricot GJ
    Adv Enzyme Regul; 1989; 28():335-56. PubMed ID: 2576178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside and non-nucleoside IMP dehydrogenase inhibitors as antitumor and antiviral agents.
    Franchetti P; Grifantini M
    Curr Med Chem; 1999 Jul; 6(7):599-614. PubMed ID: 10390603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical consequences of resistance to tiazofurin in human myelogenous leukemic K562 cells.
    Jayaram HN; Zhen W; Gharehbaghi K
    Cancer Res; 1993 May; 53(10 Suppl):2344-8. PubMed ID: 8097964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture.
    Lee HJ; Pawlak K; Nguyen BT; Robins RK; Sadée W
    Cancer Res; 1985 Nov; 45(11 Pt 1):5512-20. PubMed ID: 2865005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationships between the cytotoxicity of tiazofurin and its metabolism by cultured human lung cancer cells.
    Carney DN; Ahluwalia GS; Jayaram HN; Cooney DA; Johns DG
    J Clin Invest; 1985 Jan; 75(1):175-82. PubMed ID: 2856924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consequences of IMP dehydrogenase inhibition, and its relationship to cancer and apoptosis.
    Jayaram HN; Cooney DA; Grusch M; Krupitza G
    Curr Med Chem; 1999 Jul; 6(7):561-74. PubMed ID: 10390601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of antimetabolite action by dibromodulcitol in cell culture.
    Oláh E; Kremmer T; Boldizsár M
    Adv Enzyme Regul; 1985; 24():155-75. PubMed ID: 3835819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.